| pubmed-article:17957792 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17957792 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17957792 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:17957792 | lifeskim:mentions | umls-concept:C0007137 | lld:lifeskim |
| pubmed-article:17957792 | lifeskim:mentions | umls-concept:C0460004 | lld:lifeskim |
| pubmed-article:17957792 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:17957792 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:17957792 | lifeskim:mentions | umls-concept:C1850775 | lld:lifeskim |
| pubmed-article:17957792 | lifeskim:mentions | umls-concept:C1954261 | lld:lifeskim |
| pubmed-article:17957792 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:17957792 | pubmed:dateCreated | 2007-12-20 | lld:pubmed |
| pubmed-article:17957792 | pubmed:abstractText | YKL-40 is a glycoprotein secreted by macrophages, neutrophils and malignant tumor cells. Elevated serum levels of YKL-40 are associated with poor prognosis in several malignancies. In this study, we examined the prognostic value of serum YKL-40 before treatment and during follow-up in patients with squamous cell carcinoma of the head and neck (HNSCC). YKL-40 was determined by ELISA retrospectively in serum from 173 patients with primary HNSCC before treatment and up to 2 years after treatment. Median follow-up time was 7.9 years. YKL-40 protein expression in tumor biopsies was assessed by immunohistochemistry in 50 patients. Pretreatment serum YKL-40 was elevated in 53%. Patients with high serum YKL-40 had shorter survival than patients with normal serum YKL-40 (33 vs. 84 months; p = 0.008). Multivariate Cox analysis including pretreatment serum YKL-40, age, sex, primary tumor site, TNM classification and treatment demonstrated that TNM classification (HR = 2.61, p = 0.02) and serum YKL-40 (log-transformed continuous variable: HR = 1.55, p < 0.0001) were independent prognostic variables of overall survival (OS). Multivariate Cox analysis demonstrated that TNM classification (HR = 5.77, p = 0.001) and serum YKL-40 (dichotomous variable: HR = 2.75, p = 0.01) were independent predictors of recurrence-free survival. During follow-up after radiotherapy, a high serum YKL-40 (log-transformed continuous variable) in patients with TNM Stage III and IV disease predicted poorer OS within 6 months (HR = 1.95, p < 0.0001). Immunohistochemical analysis showed YKL-40 expression in the malignant tumor cells. In conclusion, serum YKL-40 was demonstrated to be an independent prognostic biomarker of recurrence-free and overall survival in patients with HNSCC. | lld:pubmed |
| pubmed-article:17957792 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17957792 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17957792 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17957792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17957792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17957792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17957792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17957792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17957792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17957792 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17957792 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:17957792 | pubmed:issn | 1097-0215 | lld:pubmed |
| pubmed-article:17957792 | pubmed:author | pubmed-author:PricePaul APA | lld:pubmed |
| pubmed-article:17957792 | pubmed:author | pubmed-author:KissKatalinK | lld:pubmed |
| pubmed-article:17957792 | pubmed:author | pubmed-author:JohansenJulia... | lld:pubmed |
| pubmed-article:17957792 | pubmed:author | pubmed-author:ChristensenIb... | lld:pubmed |
| pubmed-article:17957792 | pubmed:author | pubmed-author:AndersenEloE | lld:pubmed |
| pubmed-article:17957792 | pubmed:author | pubmed-author:BentzenJensJ | lld:pubmed |
| pubmed-article:17957792 | pubmed:author | pubmed-author:NielsenDorte... | lld:pubmed |
| pubmed-article:17957792 | pubmed:author | pubmed-author:BalslevEvaE | lld:pubmed |
| pubmed-article:17957792 | pubmed:author | pubmed-author:RoslindAnneA | lld:pubmed |
| pubmed-article:17957792 | pubmed:copyrightInfo | (c) 2007 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:17957792 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17957792 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:17957792 | pubmed:volume | 122 | lld:pubmed |
| pubmed-article:17957792 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17957792 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17957792 | pubmed:pagination | 857-63 | lld:pubmed |
| pubmed-article:17957792 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:meshHeading | pubmed-meshheading:17957792... | lld:pubmed |
| pubmed-article:17957792 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:17957792 | pubmed:articleTitle | High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. | lld:pubmed |
| pubmed-article:17957792 | pubmed:affiliation | Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark. anne.roslind@dadlnet.dk | lld:pubmed |
| pubmed-article:17957792 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17957792 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:17957792 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:1116 | entrezgene:pubmed | pubmed-article:17957792 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17957792 | lld:entrezgene |
| lhgdn:association:62525 | lhgdn:found_in | pubmed-article:17957792 | lld:lhgdn |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17957792 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17957792 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17957792 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17957792 | lld:pubmed |
